Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
World game at war: why some European nations have threatened a World Cup boycott 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SAN DIEGO, April 26, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University.
The CD3E model expresses the human form of CD3E and is phenotypically normal with levels of T, B, and NK cells comparable to control. These features make it an ideal model for determining the efficacy of CD3 targeted T cell redirecting therapies through direct assessment of T cell activation, antigen recognition and related intracellular signal transduction pathways.
“Data generated from our new CD3E models demonstrate their unique ability to guide development of bispecific T cell engagers and other T cell redirecting therapies,” said Dr. Davy Ouyang, Director of Translational Oncology at CrownBio. “We are very excited about the potential these innovative models have to uncover new insights in the discovery and development of cutting-edge I/O agents.”
Learn more about CrownBio’s new CD3E model by visiting https://www.crownbio.com/immuno-oncology/hugemm/cd3e-mouse-model
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
About NBRI of Nanjing University
NBRI is a leading company in China to provide high-quality human disease related animal models for biomedical community as well as pharmaceutical companies. With more than 10 years’ practice, NBRI has the vision and is striving to become world-class one-stop service center for generating, phenotyping and distributing the customized genetically engineering murine models for partners all across the world.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
